Form 4: Aquestive Therapeutics Director Receives Stock Options
Director Equity Grant
Director Abigail L. Jenkins was granted 50,500 non-qualified stock options in Aquestive Therapeutics, Inc.
Summary
- Director Abigail L. Jenkins received a grant of 50,500 non-qualified stock options on June 10, 2026.
- The options have an exercise price of $3.99 per share.
- The options are scheduled to vest in full on June 10, 2027, contingent upon continuous service.
- The expiration date for these options is June 10, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention incentive for key leadership personnel.
Negatives
- Potential for future shareholder dilution upon the exercise of these options.
Risks
- Vesting is subject to the director's continuous service with the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation grant.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder interests in the biotechnology sector.
Comparison to Industry Standards
- The use of time-based vesting (one-year cliff) is consistent with standard equity compensation practices for board members in mid-cap pharmaceutical companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Abigail L. Jenkins authorized several individuals to act as attorneys-in-fact for SEC filing purposes. | 04/22/2026 | Standard administrative procedure to ensure timely compliance with SEC reporting requirements. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options on June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/22/2026 | Execution date of the Power of Attorney. |
| 06/10/2026 | Grant date of the stock options. |
| 06/10/2027 | Vesting date for the 50,500 stock options. |
| 06/10/2036 | Expiration date of the stock options. |
Keywords
Aquestive Therapeutics, AQST, Director Compensation, Stock Options, SEC Form 4, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.